XML 121 R101.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (47,187) $ (28,845)
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Depreciation and amortization 398 464
Gain on PPP loan forgiveness   (828)
Loss on conversion of convertible notes   3,416
Loss on equity issuance 8,312  
Change in fair value of tranche and warrant liabilities 2,186 379
Discount amortization and amortization of deferred financing costs   1,743
Share-based compensation expense 368 109
Gain (loss) on disposal of fixed assets 310 (4)
Milestone payment to Dynavax 1,000 1,000
Changes in operating assets and liabilities:    
Accounts receivable (200) (741)
Inventory (179) (725)
Prepaid expenses (2,592) (1,840)
Operating lease right-of-use assets 112  
Operating lease liabilities (87)  
Accounts payable and accrued expenses 5,246 3,175
Net cash used in operating activities (32,313) (22,697)
Cash flows from investing activities:    
Purchases of property and equipment (655) (1,097)
Milestone payment to Dynavax (1,000) (1,000)
Cash paid for intellectual property and licenses (131) (161)
Net cash used in investing activities (1,786) (2,258)
Cash flows from financing activities:    
Proceeds from issuance of preferred stock 13,499 51,900
Proceeds from exercise of Series B preferred stock warrants   117
Payments on finance lease liabilities (131)  
Repayments on term loan (including $254 balloon payment)   (1,348)
Net proceeds from issuance of convertible notes   45
Cash proceeds from the exercise of stock options and warrants for common stock 94 54
Net cash provided by financing activities 13,462 50,768
Increase (decrease) in cash, cash equivalents and restricted cash (20,637) 25,813
Cash, cash equivalents and restricted cash, beginning of period 30,301 4,488
Cash, cash equivalents and restricted cash, end of period 9,664 30,301
Cash paid during the year for:    
Interest   18
Income taxes 9 3
Supplemental disclosure of noncash items:    
Value of warrants issued with convertible notes   10
Transfer of warrant liability to preferred stock upon exercise of warrants   3,397
Fixed asset purchases included in trade payables and accrued expenses $ 12  
Put option liability transferred to Additional paid-In capital   5,210
Carrying value of convertible notes and accumulated interest transferred to preferred stock   $ 49,118